Related Experiment Video
Updated: Jul 4, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Sustained Clinical Response to Immunotherapy Followed by BET Inhibitor in a Patient with Unresectable Sinonasal NUT
Harriet Herbison1, Sidney Davis2, David Nickless3
1Department of Medical Oncology, Monash Health, Clayton, Victoria, Australia.
Abstract:
NUT carcinomas (NCs) are a group of rare tumors that can occur anywhere in the body and are defined by the fusion of the nuclear protein in testis (NUTM1) resulting in increased transcription of proto-oncogenes. NCs have a poor prognosis that varies according to the site of origin with an urgent need to develop new treatment strategies. Case reports on immunotherapy in pulmonary NC have been published, and bromodomain and extraterminal (BET) inhibitors have shown activity in NC in phase I/II trials. We present the case of a 27-year-old woman with an unresectable sinonasal NC who had a sustained clinical response to both immunotherapy and BET inhibitor therapy. This is the first reported case of immunotherapy in sinonasal NC, and it highlights the different responses to a range of treatments including BET inhibitor therapy. This case supports the theory that NCs arising from different primary sites have differing prognoses.
Insights
This case study shows a patient with sinonasal NUT carcinoma (NC) responding well to immunotherapy and BET inhibitors. It highlights varying NC prognoses and treatment responses based on tumor origin.
Area of Science:
- Oncology
- Genetics
Background:
- NUT carcinoma (NC) is a rare, aggressive cancer defined by NUTM1 gene fusions, leading to poor prognoses.
- Current treatment strategies for NC are limited, necessitating exploration of novel therapeutic approaches.
Observation:
- A 27-year-old woman with unresectable sinonasal NC received immunotherapy and a bromodomain and extraterminal (BET) inhibitor.
- The patient experienced a sustained clinical response to the combined treatment regimen.
Findings:
- This is the first reported case of successful immunotherapy in sinonasal NC.
- The patient's response suggests differential therapeutic sensitivities of NC based on primary tumor site.
Implications:
- This case provides valuable insights into the efficacy of immunotherapy and BET inhibitors for sinonasal NC.
- Further research into site-specific NC treatments is warranted to improve patient outcomes.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
07:00Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas
Published on: February 28, 2019
